This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sequenom's Management Presents At Barclays Capital 2012 Global Healthcare Conference (Transcript)

Sequenom, Inc. ( SQNM)

Barclays Capital 2012 Global Healthcare Conference Call

March 14, 2012 4:15 pm ET


Ronald M. Lindsay – Executive Vice President, Research & Development


C. Anthony Butler – Barclays Capital


C. Anthony Butler – Barclays Capital

Good afternoon. Thank you for bearing with us in the late afternoon. That it’s being pleasure to introduce Ron Lindsay, who is the EVP of R&D or the Head of R&D at Sequenom; also Paul Maier, who is the CFO with us as well.

Format this afternoon will be, after Lindsay will provide some formal remarks, if there is time toward the end, we’ll open the session to a couple of questions, otherwise we’ll move to the breakout following Dr. Lindsay’s comments. Ron, thanks for coming.

Ronald M. Lindsay

Thank you, Tony, and good afternoon, everyone. I realize this is the last presentation of this session of the meeting at least that I stand between you and the room, the bar, the beach or your flight home. So, I’ll be as brief and concise as possible.

What I would like to do in the next 15 to 20 minutes is run through some slides that I think highlight a snapshot of our overall results for 2011 as a company and we presented this in some detail at our earnings call last week. So you can still refer to that.

Then outline our goals for 2012. This was something, we as a management team, always do, try to always work towards goals that we set out clearly for everybody to see. And then spend the predominant part of our presentation on the progress of our T21 test since we launched in October of last year.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.71 -0.57%
FB $119.23 1.20%
GOOG $710.01 1.20%
TSLA $215.15 1.70%
YHOO $37.21 0.73%


Chart of I:DJI
DOW 17,741.66 +80.95 0.46%
S&P 500 2,055.63 +5.00 0.24%
NASDAQ 4,726.64 +9.5460 0.20%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs